Pursuant to section 23(1) of the Medicines Act 1981, the Minister of Health hereby provisionally consents to the sale, supply or use in New Zealand of the new medicine set out in the Schedule hereto:
|Active Ingredient:||Perindopril erbumine 8mg|
|New Zealand Sponsor:||Servier Laboratories NZ Limited|
|Manufacturers:||Servier (Ireland) Industries Limited, Arklow, Ireland
Les Laboratoires Servier Industrie, Gidy, France
The medicine may only be marketed or distributed when no other perindopril erbumine medicine with consent under section 20 of the Medicines Act 1981 is available in the New Zealand market, or to meet sole tender obligations.
Note: This consent is valid until 22 January 2023.
Dated this 5th day of September 2022.
CHRIS JAMES, Group Manager, Medsafe, Ministry of Health (pursuant to delegation given by the Minister of Health on 11 September 2013).
Note: This notice replaces notices published in the New Zealand Gazette, 9 June 2022, Notice No. 2022-go2279 and New Zealand Gazette, 10 August 2022, Notice No. 2022-go3356.